Bank of America Merrill Lynch 20230213_HORIZON THERAPEUTICS PLC_38.5 (b)_IE (8865P)
14 Fevereiro 2023 - 7:38AM
UK Regulatory
TIDMTTM TIDMHZNP
RNS Number : 8865P
Bank of America Merrill Lynch
14 February 2023
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT,
1997,
TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED
INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader BofA Securities, Inc.
Company dealt in HORIZON THERAPEUTICS PLC
-------------------------
Class of relevant security to which the Common - IE00BQPVQZ61
dealings being disclosed relate(Note 1)
-------------------------
Date of dealing 13/02/2023
-------------------------
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing)
in the class of relevant security
dealt in (Note 2)
Class of relevant security: Common IE00BQPVQZ61
Long Short
----------------- ------------------
Number % Number %
-------- ------- -------- --------
(1) Relevant securities 357,384 0.156% 76,044 0.033 %
-------- ------- -------- --------
(2) Derivatives (other than options): 307,381 0.135% 314,265 0.138%
-------- ------- -------- --------
(3) Options and agreements to purchase/sell: 0 0% 37,600 0.016%
-------- ------- -------- --------
Total 664,765 0.291% 427,909 0.187%
-------- ------- -------- --------
(b) Interests and short positions in relevant securities
of the company, other than the
class dealt in (Note 2)
Class of relevant security:
Long Short
------------ ------------
Number % Number %
------- --- ------- ---
(1) Relevant securities 0 0% 0 0%
------- --- ------- ---
(2) Derivatives (other than options): 0 0% 0 0%
------- --- ------- ---
(3) Options and agreements to purchase/sell: 0 0% 0 0%
------- --- ------- ---
Total 0 0% 0 0%
------- --- ------- ---
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 4)
Purchase 2 109.56 USD
------------------------------ ------------------------
Purchase 1,100 109.505 USD
------------------------------ ------------------------
Purchase 3,154 109.51 USD
------------------------------ ------------------------
Purchase 330 109.51 USD
------------------------------ ------------------------
Purchase/sale Number of relevant securities Price per unit (Note 4)
Sale 4,300 109.6 USD
------------------------------ ------------------------
Sale 300 109.61 USD
------------------------------ ------------------------
Sale 100 109.605 USD
------------------------------ ------------------------
Sale 300 109.72 USD
------------------------------ ------------------------
Sale 330 109.51 USD
------------------------------ ------------------------
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD (Note 5) (Note 6) (Note 4)
Swaps Increasing a Short Position 36 109.513 USD
---------------------------- ------------------------------ ---------------
(c) Options transactions in respect of existing relevant
securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry date Option money paid/ received
name, selling, securities price e.g. American, per unit (Note 4)
e.g. call purchasing, to which European
option varying the option etc
etc. relates (Note
7)
N/A N/A N/A N/A N/A N/A N/A
------------- --------------- --------- ---------------- ------------ ------------------------------
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option unit (Note 4)
N/A N/A N/A
---------------------- --------------------
(d) Other dealings (including transactions in respect
of new securities) (Note 3)
Nature or transaction Details Price per unit
(Note 7) (if applicable) (Note 4)
Collateral Delivery Collateral Delivery of 66,900 shares N/A
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting rights
or future acquisition or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 38.5(b) attached? (Note 8) No
Date of disclosure 14/02/2023
Contact name Frank Lui
-----------------------
Telephone number +44207 996 6418
-----------------------
Name of offeree/offeror with which connected AMGEN INC
-----------------------
Nature of connection (Note 9) Advisor to - AMGEN INC
-----------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ISEFLFVIFEISLIV
(END) Dow Jones Newswires
February 14, 2023 05:38 ET (10:38 GMT)
Amgen (LSE:0R0T)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Amgen (LSE:0R0T)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
